Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr

Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023

Briefs: Morepen Laboratories and Zydus Lifesciences

The company is addressing these observations

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.

Morepen Laboratories net profit up 189%

R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave

CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors

The event will be attended by 35,000+ industry professionals

Morepen Board proposed dividend after 23 years

Scores highest PAT of Rs. 118 crore in FY25

Morepen to launch new fatty lever drug ‘Resmetirom’

Morepen to add 1,000 medical representatives

The company is targeting a Rs. 1,000 crore finished dosages business within the next five years